Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention

Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary... Letters (Hjelmgren, Bergström); Department of Molecular and Clinical Medicine, proximately 4%) vs major bleeding (1.6% to 3.6%). The use of Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden dual antiplatelet therapy (DAPT) following percutaneous coro- (Hjelmgren, Bergström); Institute of Clinical Sciences, Department of Radiology, nary intervention without atrial fibrillation is recommended Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden based on randomized studies including more than 220 000 (Brandberg); Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden (Brandberg); Region Västra Götaland, Department of patients. Recently, trials on the use of double antithrombotic Drug Treatment, Sahlgrenska University Hospital, Gothenburg, Sweden therapy (DAT) and triple antithrombotic therapy (TAT) in pa- (Ohlsson). tients with both atrial fibrillation and the need for DAPT uni- Corresponding Author: Claes Ohlsson, MD, PhD, Centre for Bone and Arthritis vocally demonstrated lower bleeding rates when using DAT Research, Klin Farm Laboratory, Vita Stråket 11, SE-41345 Gothenburg, Sweden (claes.ohlsson@medic.gu.se). compared with TAT. However, none of these trials was pow- ered for efficacy regarding ischemic end points. Accepted for Publication: August 17, 2020. The updated network meta-analysis published in JAMA Published Online: October 14, 2020. doi:10.1001/jamacardio.2020.4880 Cardiology includes 11 532 patients and highlights important Author Contributions: Dr Ohlsson had full access http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention

Loading next page...
 
/lp/american-medical-association/antithrombotic-strategies-in-patients-with-atrial-fibrillation-and-40E0ognhbL
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.4753
Publisher site
See Article on Publisher Site

Abstract

Letters (Hjelmgren, Bergström); Department of Molecular and Clinical Medicine, proximately 4%) vs major bleeding (1.6% to 3.6%). The use of Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden dual antiplatelet therapy (DAPT) following percutaneous coro- (Hjelmgren, Bergström); Institute of Clinical Sciences, Department of Radiology, nary intervention without atrial fibrillation is recommended Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden based on randomized studies including more than 220 000 (Brandberg); Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden (Brandberg); Region Västra Götaland, Department of patients. Recently, trials on the use of double antithrombotic Drug Treatment, Sahlgrenska University Hospital, Gothenburg, Sweden therapy (DAT) and triple antithrombotic therapy (TAT) in pa- (Ohlsson). tients with both atrial fibrillation and the need for DAPT uni- Corresponding Author: Claes Ohlsson, MD, PhD, Centre for Bone and Arthritis vocally demonstrated lower bleeding rates when using DAT Research, Klin Farm Laboratory, Vita Stråket 11, SE-41345 Gothenburg, Sweden (claes.ohlsson@medic.gu.se). compared with TAT. However, none of these trials was pow- ered for efficacy regarding ischemic end points. Accepted for Publication: August 17, 2020. The updated network meta-analysis published in JAMA Published Online: October 14, 2020. doi:10.1001/jamacardio.2020.4880 Cardiology includes 11 532 patients and highlights important Author Contributions: Dr Ohlsson had full access

Journal

JAMA CardiologyAmerican Medical Association

Published: Feb 7, 2021

References